xCELLigence RTCA Cardio: Real-Time Analysis of Cardiomyocyte Contractility and Viability

The xCELLigence RTCA Cardio system is designed for precise cardiotoxicity assessment by monitoring cardiomyocyte contractility and cell viability. Built on impedance-based technology, it tracks changes in cellular morphology, proliferation, and attachment like other RTCA systems. What sets the Cardio system apart is the precise detection of rhythmic contractility cycles in cardiomyocytes. Compatible with stem cell-derived, iPSC-derived, or primary cardiomyocytes, the Cardio system operates in a 96-well format, making it ideal for scalable and precise cardiac research.

High Throughput: Detects functional cardiotoxicity effects on both short- and long-term cardiac beating activity in a 96-well format.

Comprehensive Toxicity Assessment: Effectively evaluates general toxicity and correlates findings with arrhythmogenic activity.

Mechanism of Action Insights: Provides valuable insights into the compound's mechanism of action, aiding in drug development and safety screening.